%0 Journal Article
%T Loss of Villin Immunoexpression in Colorectal Carcinoma Is Associated with Poor Differentiation and Survival
%A Jaudah Al-Maghrabi
%A Wafaey Gomaa
%A Abdelbaset Buhmeida
%A Mohmmad Al-Qahtani
%A Mahmoud Al-Ahwal
%J ISRN Gastroenterology
%D 2013
%R 10.1155/2013/679724
%X Background and Aims. Villin is a highly specialised protein and is expressed in intestinal and renal proximal tubular epithelium. It was detected in colorectal carcinomas (CRC) and other nongastrointestinal tumours. The aim of the current study is to investigate the immunohistochemical expression of villin in a subset of primary CRC and determine its relation to tumour differentiation, invasion, nodal metastasis, recurrence, and disease-free survival. Patients and Methods. Paraffin blocks of 93 cases of CRC were retrieved constituting 93 primary CRC and 58 adjacent normal mucosa. Immunohistochemistry was performed using antivillin antibody. The extent (%) of villin immunoexpression was categorised for statistical analysis. Statistical tests were used to determine the association of villin with clinicopathological characteristics: age, sex, tumour location, tumour size, depth of invasion, tumour grade, nodal metastasis, lymphovascular invasion, margin status, recurrence, and survival. Results. Villin immunostaining results showed that villin is downregulated in CRC. Villin has no association with age, sex, tumour location, depth of invasion, nodal metastasis, lymphovascular invasion, margin status, and recurrence. However, villin is expressed in higher rate in CRC less than 5£¿cm, well- and moderately differentiated CRC. Poor survival was associated with tumour with low villin immunoexpression. Conclusion. Villin was downregulated in CRC. Villin immunoexpression in CRC is associated with better survival, well-differentiated tumours, and small-sized tumours. Villin has no significant association with disease recurrence or nodal metastasis. More in vivo and in vitro studies are required for further elucidation of how villin may be involved in CRC. 1. Introduction Although 70% of colorectal carcinoma (CRC) cases undergo a curative surgery, 50% of surgically cured patients will have at a time an advanced local recurrence or metastases [1]. CRC is a common type of cancer with a considerably poor prognosis and mortality all over the world. The extent of local invasion and tumour metastasis are important factors to determine disease outcome. Distant metastases aggravate treatment failure, and patients will be subjected to palliative treatment. Molecular markers of metastasis are essential to improve treatment protocols [1, 2]. Understanding the molecular pathology underlying CRC needs continuous efforts to discover more prognostic molecules to predict disease outcome and improve therapeutic interventions. The Saudi Arabian National Cancer Registry in 2005 showed
%U http://www.hindawi.com/journals/isrn.gastroenterology/2013/679724/